Descartes Systems Group (DSGX) is a strong buy with robust growth, AI-driven supply chain solutions, and attractive entry points for investors. Read the latest analysis on the stock here.

Descartes Underwriting, the parametric risk transfer specialist, has adopted mea Platform’s artificial intelligence (AI) ...

LLDAS response rate observed in patients with SLE who received Descartes-08 in Phase 2 open-label trial reaching Month 3 follow-up (n=3) ...

Discover why Cartesian Therapeutics, Inc. earns a Buy rating with strong CAR-T pipeline progress and market growth in ...

Automation and AI emerge as critical differentiators for logistics services providers facing global instability, tariff volatility and cost ...

Record Services Revenues WATERLOO, Ontario and ATLANTA, June 04, 2025 (GLOBE NEWSWIRE) -- The Descartes Systems Group Inc. (TSX:DSG) (Nasdaq:DSGX) announced its financial results for its fiscal 2026 ...

Cartesian Therapeutics (RNAC) announced positive initial data from its ongoing Phase 2 open-label trial of Descartes-08 in patients with systemic ...

Detailed price information for Descartes Sys Group (DSGX-Q) from The Globe and Mail including charting and trades.

By aggregating e-commerce operations on a centralised platform, the cloud-based Descartes solution increased efficiency and ...

Descartes Underwriting, a specialist in corporate parametric re/insurance solutions for climate and emerging risks, has ...